Paladin Capital Group: Biotech Firm Revolutionizing Amino-Acid Manufacturing Closes $12 Million Series A Financing Round
October 30, 2024
October 30, 2024
WASHINGTON, Oct. 30 -- Paladin Capital Group, an entity that says it supports and grows companies through venture investment and growth capital, issued the following news:
SAN LEANDRO, CA -- Aralez Bio, a platform technology company with a proprietary enzymatic approach for designing and manufacturing noncanonical amino acids (ncAAs), announced the close of its oversubscribed $12 million Series A financing today.
The round was led by Spero Ventures with matched investme . . .
SAN LEANDRO, CA -- Aralez Bio, a platform technology company with a proprietary enzymatic approach for designing and manufacturing noncanonical amino acids (ncAAs), announced the close of its oversubscribed $12 million Series A financing today.
The round was led by Spero Ventures with matched investme . . .